image description

*Data presented refer to treatment with once-daily SPIRIVA® 18 μg via HandiHaler® or SPIRIVA® Respimat® 2.5 μg (two puffs, once daily).

1. Boehringer Ingelheim GmbH, data on file. 2. IMS Health Data, Q4 2015. 3. National Institutes of Health. Accessed March 23, 2016. 4. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease; Updated 2016. Accessed January 5, 2016.